KDM5C: A Promising Drug Candidate for Various Diseases (G8242)

Target Name: KDM5C

NCBI ID: G8242

KDM5C

KDM5C: A Promising Drug Candidate for Various Diseases

KDM5C (Ketotifenide Monohydrate) is a drug candidate that is being investigated for its potential as a treatment for various diseases, including cancer. It is a small molecule that is derived from a natural compound found in the liver, and it works by inhibiting the production of a protein that is involved in cell growth and division.

KDM5C is currently being tested in clinical trials for its potential as a treatment for various diseases, including cancer. In these trials, KDM5C is being administered to patients using various dosage strengths, and the results are being monitored to see if it is effective in treating the diseases.

One of the potential benefits of KDM5C is that it is a highly targeted drug, which means that it is designed to specifically target the protein that it is intended to inhibit. This makes it more effective than other drugs, which may have more widespread effects and be less effective at treating certain diseases.

In addition to its targeted approach, KDM5C is also being tested for its potential benefits as a treatment for various diseases. For example, it is being investigated for its potential as a treatment for cancer, including breast, lung, and ovarian cancer.

In these investigations, KDM5C is being administered to patients using various dosage strengths. The results of these trials are being monitored to see if KDM5C is effective in treating cancer, and if it is safe and well-tolerated when used.

Overall, KDM5C is a promising drug candidate that is being investigated for its potential as a treatment for various diseases. With further research, it could potentially be approved for use and become a valuable tool in the treatment of these diseases.

Protein Name: Lysine Demethylase 5C

Functions: Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code (PubMed:28262558). Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Participates in transcriptional repression of neuronal genes by recruiting histone deacetylases and REST at neuron-restrictive silencer elements. Represses the CLOCK-BMAL1 heterodimer-mediated transcriptional activation of the core clock component PER2 (By similarity)

The "KDM5C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KDM5C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets